Second 3B Future Health Fund launched

3B FUTURE HEALTH GP S.a.r.l. launches the 3B Future Health Fund II. The Fund is focused on early-stage investment opportunities in areas of high unmet patient need and follows the success of 3B Future Health Fund I, formerly known as Helsinn Investment Fund. The investment focus for the Fund is on US and European-based start-ups working in the field of oncology and rare diseases therapeutics.

Fund II is backed by the same diversified and experienced team as Fund I with a broad network and drug development knowledge; bringing together expertise in drug discovery and research and development, drug manufacturing, business development and licensing as well as investment fund management. The Fund is incorporated in Luxembourg where the anchor investors will be the Helsinn Group and the Braglia family. The Fund targets 100M EUR partnering with experienced private and institutional investors. 

Riccardo Braglia, Chairman of Helsinn Group and General Partner of the fund said: “I’ve been delighted at the success of the first fund. 3B Future Health Fund II will be underpinned by the same core principles of quality, integrity and respect that characterize my family and the Helsinn Group as a whole. We are excited by the prospects of the healthcare sector and have high aspirations for this fund.”

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care and rare disease products and a broad development pipeline. The company with more than 700 employees was founded in 1976 and is based in Lugano. The Helsinn Investment Fund was founded in 2016.

(Press release / SK)